



**Northumbria
University**
NEWCASTLE

Deep lung fine aerosols as a novel sample for translational biomarker discovery

Dr Sterghios A. Moschos FRSC FIBMS FHEA MRSB

Associate Professor, Cellular and Molecular Sciences

Founder and Chief Scientific Officer, PulmoBioMed Ltd.

Mastodon: @docmoschos@scicomm.xyz

Twitter: @docmoschos

Overview

- Exhaled breath
 - Composition
 - Anatomy
 - Physics
- Clinical use: progress to date
 - Volatile compounds
 - Condensates
- The impact of COVID-19 research
- Future directions

Exhaled Breath



Breath is a mix of:


- Volatile compounds
- Aerosols.
- Non-volatile biological molecules.

Biomarkers:

- Lung infections.
- Liver diseases.
- Multiple cancers:
 - Blood.
 - Breast.
 - Brain.

Exhaled breath: origin, content

The Airway Tree




Upper airways

Lower airways




Airway lining fluid droplets
Molecular water

Inhaled particles




Exhaled breath: origin, content



Exhaled Breath Condensation (EBC): physics


Ambient conditions

25°C, 50% RH




No condensation

12°C, 50% RH



0.19 g/kgr water/air

-20°C, 50% RH



11.1 g/kgr water/air

Clinical adoption: Volatile compounds

Nitric Oxide

- Produced in response to inflammation
- Kharitonov *et al.* 1994 Lancet
- 2003 FDA approval
- 2017 NICE adoption


¹³C compounds

- *H. pylori*
- Gastric emptying
- Disaccharide malabsorption
- Small bowel bacterial overgrowth

Multi-analyte

- COVID-19 tests
- Singapore, NL, USA
EUA
 - High variation reports (UK)
 - Specificity unclear
 - NL field use failed
 - Limited news otherwise

Fractional exhaled NO



Challenges to EBC clinical use

- Reproducibility.
- Contamination:
 - Saliva.
 - Ambient.
- Sample loss.
- Safety.
- Upper vs deep lung separation.

RTube™



Saliva contamination


EcoScreen™



Sample lost in black tube
17Kg + weight

Is SARS-CoV-2 airborne?

- Leung *et al.* 2020, 30-40% +ve by fraction, n=17.
- Ryan *et al* 2020: 66-93% +ve R-Tube, test dependent, n=16
- Sammadar *et al* 2021: 23-84% masks +ve days 1-4, n=44.
- Zhou *et al.* 2021, Ma *et al.* 2020: 22-27%, n=9, 52, late in clinical stage
- Feng *et al.* 2021, n=21, all -ve, high dilution.



Is SARS-CoV-2 airborne?

- 0-93% positivity across studies
 - Saliva is a known source of SARS-CoV-2
 - Most devices cannot exclude salivary / large droplets / fomites.



**Dissolvable strips inside mask- fomite
And handling contamination risk**

Is SARS-CoV-2 airborne?

- 0-93% positivity across studies
 - Saliva is a known source of SARS-CoV-2
 - Most devices cannot exclude salivary / large droplets / fomites.



COVID-19 positive but **saliva in straw and box**

Is SARS-CoV-2 airborne?


- 0-93% positivity across studies
 - Virus detected in fine aerosols (<5 um)
 - Levels increase with speech < coughing << singing
 - Cannot exclude fomites / airflow change effects at cone end.



COVID-19 positive but air/skin follicle contamination

Is SARS-CoV-2 airborne?

- 0-93% positivity across studies
 - Adequate particle separation.
 - No virus in fine aerosols
 - Could be sub-sampling false negative




35 Liter container

Est. 26% of resulting air mix adequately sampled.

Is SARS-CoV-2 airborne?

- 0-93% positivity across studies
 - Adequate particle separation.
 - No virus in fine aerosols
 - Could be sub-sampling false negative
 - Same patients 'positive' in traditional EBC sample (saliva)



Some positive samples in this device from same study as previous slide

Main tube can be contaminated w/ drool


PBM-HALE™: an alveolar condensate collector



WO2017153755A1: exhaled breath collector – granted UK, USA, JP; WO2019053423A1: cascade impactor array – granted UK, EU

Pictures used with permission

PBM-HALE™: the platform collects




Large droplets

- By inertial impaction

Fine aerosols


- By cold condensation



Inhalation phase FA cooling

- 5 sec "stabilization"
- Tidal exhalation (0.5L/3 sec)
- No inhalation via the device
- Terminal 48mL of exhalation condensed

Time = 0 s



5 sec breathing cycle; 10,000 iteration convergence

Data by Mr Saqib Ali, Dr Madeleine Combrink

Inhalation phase FA cooling

Exhalation cycle timepoint (sec)

0

1



2

3

4

5

6




Temperature (Fluid) [°C]

PBM-HALE™ captures
48 ml of FA
from the terminal 83 ml of exhalation

5 sec breathing cycle; 10,000 iteration convergence

Data by Mr Saqib Ali, Dr Madeleine Combrink

Exhaled particles swell due to condensation




- <5 μm particle count drops
- >1 μm particle count increases
- Effect maximal at -80°C


- PBM-HALE swells particles to alter aerodynamic properties enhancing capture.

Fine aerosol capture performance


Condensation Temperature



Day to day variability



Sampling duration



Viability bacteria in FA EBC

FA Condensation Temperature


-ve control




Dry ice (-78.5°C)



Wet ice (0°C)




LD



2 min sampling period

n = 5, blood agar

FA and LD Microbiota are distinct




Invasive sampling
dominated by
firmicutes, bacteroides.

60% proteobacteria
reported only in
healthy lung resection


(Sze MA *et al. Am. J. Resp. Crit. Care Med.* 2012)

FA and LD Microbiota are distinct



Phylum level



Genus level



No FA EBC salivary amylase contamination



Saliva enzyme levels at least 1,750x less in EBC than in saliva (drool) or device saliva trap even after 30 min.

n = 5.

Metabolomics of EBC FA

Compound	RMM (g/mol)	RT [min]	Relative ion abundance
1-hexadecyl-glycero-3-phosphate	396.3	1.002	810,094
monoacylglyceride	352.3	1.02	281,866
LysoPA	410.2	1.032	968,316
Palmitoleylethanolamide	297.3	1.047	187,282
eicosatetraenoate	335.2	1.054	348,544
Linoleamide	279.3	1.061	216,809
Cuscohygrine	224.2	1.067	723,759
N-Decanoylglycine	229.2	1.156	2,612,124
N-Nonanoylglycine	215.2	1.198	1,942,872
cis-3-Hexenyl b-primeveroside	394.2	1.221	160,089
N-Lauroylglycine	257.2	1.923	286,977
N-Undecanoylglycine	243.2	2.072	227,826
phosphatidylethanolamine	837.5	2.388	381,518
Gambogic acid	628.3	2.536	416,778
2-Hexenoylcarnitine	257.2	3.062	994,821
L-argininium	175.1	3.367	502,141
N-Acetylputrescine	130.1	3.519	192,382

Compounds detected by MS1:

- C6-C24 fatty acids.
- Phospholipids & precursors.
- Glycans.
- Medications.
- Drugs of abuse.
- Dietary compounds.

Additionally:

- 20 multiple HDBM hits.
- 104 novel compounds.

Aerosolised SARS-CoV-2 VLP Capture

PariBoy Classic nebuliser:

- Mean droplet diameter 3.5 μm
- 67% of mass in $< 5 \mu\text{m}$
- 5 min sampling

Particle types:

- Polystyrene beads (118 nm, -71 mV, diH₂O)
- Neutral liposomes (168 nm, -20 mV, PBS)
- Negative liposomes (188 nm, -72 mV, PBS)
- Lentiviral VLP (MLV; 193 nm, -31 mV, PBS)
- SARS-CoV-2 VLPs (155 nm, -17 V, PBS)



Aerosolised SARS-CoV-2 VLP Capture

PariBoy Classic nebuliser:

- Mean droplet diameter 3.5 μm
- 67% of mass in $< 5 \mu\text{m}$

Particle types:

- Polystyrene beads (118 nm, -71 mV, diH₂O)
- Neutral liposomes (168 nm, -20 mV, PBS)
- Negative liposomes (188 nm, -72 mV, PBS)
- Lentiviral VLP (MLV; 193 nm, -31 mV, PBS)
- SARS-CoV-2 VLPs¹ (155 nm, -17 V, PBS)



Sampling conditions:

- 5 ml sample
- 5 min nebulization
- ~1.5 ml of dry ice condensate captured

Sample analysis:

- Particle size and concentration
- Fluorescent Nanoparticle tracking analysis (Malvern; 488 nm FluoSpheres, TopFluor liposomes, YFP, or scatter)
- Unfrozen input, Frozen input, Condensate.

Aerosolised SARS-CoV-2 VLP Capture



Virtually no loss of VLP size or structure

Aggregation with highly charged particles:

- Drop in concentration
- Rise in particle size
- Beads and liposomes

COVID19 Exploratory Pilot Study



Inclusion criteria:

- NP swab positive
- Within days 0-5 of symptom onset

Study size:

- $n=60$, 98% power, 10% +ve
- Interim data point: $n=30$
- $N=12$ outside inclusion criteria

Samples:

- Tidal breathing
- 5-30 min
- Fine Aerosol, NP swab

Outcome:

- 1.5 years to complete
- **No SARS-CoV-2 RNA in FA**

COVID19 Follow-up Pilot Study



Inclusion criteria:

- NP swab positive
- Within days 0-5 of symptoms

Study size:

- $n=30$
- Interim data point: $n=15$


Samples:

- Tidal breathing <30 min
- Forced expiration <15 min
- Saliva
- Fine Aerosol, Large Droplets



SARS-CoV-2 interim clinical data

FA volumes

Tidal vs singing: ~120 $\mu\text{l}/\text{min}$



Total host RNA and SARS-CoV-2 RNA




100% of singing samples positive, 1 min sample

90x increase in host total RNA yield

8.72x more sample assayed in Brazil study vs Greece study (or 2.95 cycles higher signal).

CDC multiplex assay (N1, N2, RP) and 18S rRNA in 3 technical triplicates; No RP detected; empty shapes: <3 replicates, or only 1 assay fully positive (inconclusive)

FA host RNA not due to saliva contamination



- No 18S rRNA (total RNA) correlation between:
 - Saliva vs LD ($p = 0.8718$)
 - Saliva vs FA ($p = 0.6670$)
- FA total RNA is not due to saliva contamination

Conclusions

SARS-CoV-2 in breath:

- Present in saliva
- Not found in tidal alveolar FA, LD
- High FA levels in speech
- Mode of exhalation affects rate of emission and detection.
- More than V_x needed to resolve pandemic¹

PBM-HALE™ Breath Fractions²:

- Cell membrane components
- DNA, RNA, protein
- Drugs of abuse
- Bacteria, fungi
- FA not contaminated by:
 - Saliva
 - Ambient aerosols

Future work

Beyond COVID-19

- Total RNA-SEQ
- Host cytokine changes
- Flu, RSV, TB, *Haemophilus*
- Australia & China industry collaborations
- 2 million uses per month

Asthma & paediatric wheeze

- T2 High vs T2 Low asthma
- 7 subtypes, different cytokines
 - No neutrophilic stratification test available
 - Pharma Rx development
- Bacterial infection AMR
- Infections + asthma typing = Paediatric wheeze

Acknowledgements

Moschos lab Northumbria

Dr John Henderson
Dr Andrew Nelson
Dr William Cheung
Dr Pep Canyelles-Pericas
Mr Craig Clements
Mr Declan Gardner
Miss Zoe Hewitson
Dr Louise Usher
Mr Kavita Shah
Mr Guilherme M.E. Silva
Miss Amie Wilkinson

PulmoBioMed Ltd.

Dr Huw A. Edwards
Dr Pete Hotten
Mr Jonathan Brooks
Dr Nick Bailey
Dr Theodora Mantso
Mr Saqib Ali

Federal University of Minas Gerais

Prof. Mauro M. Teixeira
Prof. Renato S. Aquiar
Dr Pedro J. Almeida
Mr Daniel C. Queiroz

University of Athens

Dr Gkikas Magiorkinis
Dr Paraskevi A. Katsaounou
Mr Edison Jajah
Mr Nikolaos Athanasiou

University of Crete

Prof Aristeides Tsatsakis
Prof George Sourvinos
Dr Alexandros Zafiropoulos
Dr Diamantis P. Kofteridis
Mr Taxiarchis Nikolouzakis

University of Ulm

Prof Jan Münch
Dr Janis Mueller
Mr Rudiger Gross
Prof Manfred Frick

University of Oxford

Prof Aris Katzourakis

